A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers

A Phase 1, Single Dose Escalation Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers

This is a single-centre, blinded, randomized, placebo controlled, dose escalation study. Up to 9 healthy male volunteers will participate in the study. This study is designed to investigate the use of delayed release tablets for colonic delivery of Brilacidin.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: Placebo; Drug: Brilacidin; Radiation: 4Mq 99mTc-DTPA

Detailed Description

Brilacidin is a fully synthetic, non-peptidic, host defense protein mimetic, and has been shown to demonstrate anti-inflammatory and antibacterial activities.

Two prototype tablets have been developed to contain 50 mg or 100 mg of Brilacidin. Matching placebo tablets have also been developed. In this Phase 1 study, the delayed release prototype tablets will be tested to confirm efficient and specific target release of Brilacidin in the colon and to assess the safety, tolerability and the pharmacokinetics of Brilacidin administered directly to the colon.

Three subjects will be enrolled into each cohort of the study. Each subject will receive one treatment at one Assessment Visit. In each cohort, two subjects will receive a Brilacidin containing dose, and one subject will receive placebo.

Cohort 1: 50 mg Brilacidin or Placebo; Cohort 2: 100 mg Brilacidin or Placebo; Cohort 3: 200 mg Brilacidin (as 2 x 100 mg Brilacidin tablets) or 2 x Placebo.

Each treatment (drug and placebo) will be radiolabelled with technetium-99m (99mTc). The radiopharmaceutical, 99mTc-DTPA, does not enter the systemic circulation and is routinely used for investigations of this type. In Cohort 1 and 2 each tablet, including placebo, will be radiolabelled to contain approximately 4 MBq 99mTc-DTPA at time of dosing. In Cohort 3 each individual tablet, active or placebo, will be radiolabelled with 2 MBq 99mTc-DTPA to give a total dose of 4 MBq per treatment.

Each tablet will be taken orally with 200 mL room temperature water with subjects in the fasted state. The gastrointestinal transit and release behavior of the tablets will be studied using gamma scintigraphy. Blood samples will be taken at pre-defined times to allow pharmacokinetic (PK) evaluation of drug absorption with respect to time and location of tablet release.

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Scotland
    • Glasgow, Scotland, United Kingdom, G4 0SF
      • BDD Pharma Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Healthy male volunteers.
2. Aged between 18 and 65 years inclusive.
3. BMI between 18 and 30 kg/m², inclusive. Body weight ≥50 kg.
4. Understands and is willing, able and likely to comply with all study procedures and restrictions.
5. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent (signed and dated) obtained before any trial-related activities.
6. Confirmed to be in general good health.

Exclusion Criteria:

1. Medical History

   1. Current or recurrent disease that, in the opinion of the PMI or medically qualified designee/physician responsible, could affect the study conduct or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure).
   2. Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures.
   3. A history of current or relevant previous non self-limiting gastrointestinal disorders.
   4. Currently suffering from disease known to impact gastric emptying, e.g. migraine, Type 1 or Type 2 diabetes mellitus.
   5. Has untreated hypertension or has hypertension under treatment.
   6. Has a diagnosis of an immunosuppressive illness or a condition requiring chronic immunosuppression.
   7. As a result of physical examination or screening investigations, and available prior to dosing evaluations, the PMI or medically qualified designee/ physician responsible considers the volunteer unfit for the study.

2. Medications

   1. Subject is scheduled to take prescribed medication within 14 days prior to the assessment visit.
   2. Subject is scheduled to take over-the-counter (OTC) medication, including vitamins and natural or herbal remedies, within 48 hours prior to the assessment visit.

3. Alcohol/Substance Abuse

   1. Recent history (within the last year) of alcohol or other substance abuse.
   2. Subject has an average weekly alcohol intake of greater than 21 units.
   3. Subject has positive urine drugs of abuse test at screening or prior to dosing evaluation.
   4. Subject has a positive breath alcohol test at screening or prior to dosing evaluation.

4. Smoking

   1. Subject has recently discontinued smoking (less than 3 months).
   2. Subject is currently a smoker or user of nicotine-containing products.
   3. Subject has a positive urine cotinine test at screening or prior to dosing evaluation.

5. Allergy/Intolerance

   1. Subject has a history of allergy to any component of the dosage form or any other allergy, which, in the opinion of the PMI or medically qualified designee/ physician responsible, contraindicates their participation.
   2. Has known allergies or intolerance to Brilacidin.
   3. Has an allergy to any of the contents of the standardised meals.
   4. Vegetarian or vegan.
   5. Suspected or diagnosed lactose intolerance.

6. Clinical Studies

   1. Participation in another clinical study (inclusive of final post-study examination) or receipt of an investigational drug within the 12 weeks before first screening visit.
   2. Previous participation in this study.
   3. Subject whose participation in this study will result in a participation in more than four studies over a twelve month period.
7. Personnel; An employee of the Sponsor, client or study site or members of their immediate family.
8. Radiation Exposure; Subject has a total dosimetry value which, in the opinion of the PMI or medically qualified designee/ physician responsible, contraindicates their participation.

9. Blood

   1. Blood donation or significant blood loss within 3 months of screening.
   2. Difficulty accessing forearm veins for cannulation or blood sampling.

10. Family Planning

    1. Subjects who are intending to father a child in the 90 days following the study or are unwilling to abstain from sexual intercourse with pregnant or lactating women.
    2. Subjects who are unwilling to use a condom/spermicide in addition to having their female partner use another form of contraception such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation if the woman could become pregnant from the time of the assessment visit until 3 months following the study.
11. Other; Non-removable metal objects such as metal plates, screws etc in their chest or abdominal area which in the opinion of the PMI or medically qualified designee/ responsible physician could affect the study conduct.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Single

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 50 mg Brilacidin tablet	Drug: Brilacidin; Brilacidin; Radiation: 4Mq 99mTc-DTPA; 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Experimental: 100 mg Brilacidin tablet	Drug: Brilacidin; Brilacidin; Radiation: 4Mq 99mTc-DTPA; 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Experimental: 200 mg Brilacidin (2 x 100 mg Brilacidin tablets)	Drug: Brilacidin; Brilacidin; Radiation: 4Mq 99mTc-DTPA; 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Placebo Comparator: Placebo tablet (replica of shape/size of 50 mg tablet)	Drug: Placebo; Placebo; Radiation: 4Mq 99mTc-DTPA; 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Placebo Comparator: Placebo tablet (replica of shape/size of 100 mg tablet)	Drug: Placebo; Placebo; Radiation: 4Mq 99mTc-DTPA; 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Placebo Comparator: Placebo (2 x replica of shape/size of 100 mg tablets)	Drug: Placebo; Placebo; Radiation: 4Mq 99mTc-DTPA; 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Site of release of radiolabel	Site of release of radiolabel determined by a qualified assessor based on gamma scintigraphy images	To 14 hours post-dose
Time to release of radiolabel	Site of release of radiolabel determined by a qualified assessor based on gamma scintigraphy images	To 14 hours post-dose
To visualise radiolabel dispersion within the colon	To visualise the disintegration and dispersion of delayed release tablets from gamma scintigraphy images of the colon	To 14 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Maximum Plasma Concentration	To 24 hours post-dose
Tmax	Time of Maximum Plasma Concentration	To 24 hours post-dose
Tlag	Lag Time	To 24 hours post-dose
AUClast	Area Under the Curve from time 0 to 24 hours	To 24 hours post-dose
AUC0-inf	Area Under the Curve from time 0 to infinity	To 24 hours post-dose
K	Terminal First Order Rate constant	To 24 hours post-dose
t1/2	Half Life	To 24 hours post-dose
Adverse Events	Number of Participants With Treatment-Emergent Adverse Events	14 days

Collaborators and Investigators

• Sponsor: Innovation Pharmaceuticals, Inc.
• Investigators: Principal Investigator: Howard Stevens, PhD, BDD Pharma Ltd

Study record dates

Study Major Dates

• Study Start (Actual): January 6, 2020
• Primary Completion (Actual): February 12, 2020
• Study Completion (Actual): February 12, 2020

Study Registration Dates

• First Submitted: January 21, 2020
• First Submitted That Met QC Criteria: January 21, 2020
• First Posted (Actual): January 27, 2020

Study Record Updates

• Last Update Posted (Actual): February 24, 2020
• Last Update Submitted That Met QC Criteria: February 21, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: BC250; 2019-003367-22 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No